The treatment, dubbed Natesto, is a self-administered formulation of testosterone dosed to the nose with the help of an applicator. …read more Source: Trimel wins FDA approval for its ‘low-T’ nasal gel
Armed with ex-Merck immunotherapy and some promising preclinical data, startup ARMO BioSciences has pulled in $30 million in venture cash to study whether its candidate can help kill cancer cells by galvanizing an immune system response. …read more Source: ARMO pockets $30M for its immunotherapy ahead of the ASCO spotlight
When the curtain goes up at ASCO here tomorrow, you can bet that one subject will dominate the entire conference: immuno-oncology. But the number of prominent players on the immunopalooza stage this year is likely to grow as analysts fix on the swelling lineup of studies that are attracting global attention from cancer patients and […]
Johnson & Johnson’s busy deal team in California has nailed down another development pact–this time zeroing in on new technology at a Berkeley biotech that will be used to expand its considerable efforts on prostate cancer R&D. …read more Source: J&J expands prostate cancer program with cancer vax tech from Aduro
Mathew Martoma, the former SAC Capital Advisors employee convicted in biotech’s largest insider trading scandal, is seeking a softer prison sentence for his role in the scheme. …read more Source: Convicted SAC trader begs for leniency after insider blowup
The Netherlands’ arGEN-X has paired up with Bayer, agreeing to share its proprietary antibody technology with the drug giant to fuel some early-stage R&D. …read more Source: Bayer taps Dutch antibody specialist for biologics discovery
Array BioPharma has watched its shares fall steadily earthward since ex-partner Amgen backed out of a diabetes deal last summer, but a new deal with Big Biotech Biogen Idec sent the company up about 5% on renewed hopes for its early-stage R&D efforts. …read more Source: Slumping Array aligns with Biogen on early autoimmune R&D […]
As promised, Valeant Pharmaceuticals has returned to the deal table with a sweetened pitch for Allergan, putting up a bigger offer with more cash and even making an uncharacteristic commitment to R&D. …read more Source: Valeant dials up its Allergan bid and throws in some R&D promises
Canada’s Trimel Pharmaceuticals, a penny stock biotech which issued a “going concern” warning about its financial status earlier this year, is touting the results of a midstage drug designed to correct female sexual disorder. …read more Source: Troubled Trimel touts effect of its female sexual disorder drug Tefina
I’ll be hosting a Twitter chat on Thursday afternoon–3:30 pm EST–with Dr. David Porter, one of the top investigators on the CAR-T team at the University of Pennsylvania. …read more Source: Turn on, tune in and tweet out for our upcoming chat on CAR-T
